Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

morning brief

- PMLiVE

Electric dreams in medicine

Treating human disease with electrical impulses dates back decades, and now pharma is exploring the concept of ‘electroceuticals’ to complement drug-based therapy

- PMLiVE

Novo Nordisk recalls insulin

Batches of prefilled NovoMix 30 pens found to have incorrect amount of diabetes treatment

- PMLiVE

GSK sets up centre to develop greener drugs

Brazil centre to focus on sustainable chemistry

- PMLiVE

China weighs heavy on GSK figures in Q3

Pharma company loses two thirds of sales in region after scandal-hit period

- PMLiVE

GSK and Genmab file Arzerra for first-line use in US

Plans progress to expand the chronic lymphocytic leukaemia drug

- PMLiVE

Novo Nordisk wins US approval for haemophilia treatment

NovoEight will be launched alongside MixPro device after gaining FDA licence

- PMLiVE

Janssen buys hepatitis C candidate from GSK

J&J subsidiary acquires rights to NS5A inhibitor

- PMLiVE

GSK hoping to file malaria vaccine next year

New phase III data backs submission plans

- PMLiVE

Novo’s Wagtmann joins Innate as chief scientific officer

He was previously head of inflammation biology at Danish pharma company

- PMLiVE

Novo backs Victoza’s prospects in Alzheimer’s

Chief science officer says phase III trial could begin in three years

- PMLiVE

GSK sells off anticoagulants for £700m

South Africa-based Aspen buys rights to Arixtra and Fraxiparine

- PMLiVE

EASD 2013: Novo Nordisk’s diabetes combination IDegLira impresses in study

Mix of Tresiba and Victoza helps 81 per cent achieve blood sugar target in phase III

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links